INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Dyne Therapeutics, Inc. – DYN

Group 1 - Dyne Therapeutics is under investigation by Pomerantz LLP for potential securities fraud or unlawful business practices involving its officers and directors [1] - On June 17, 2025, Dyne announced a delay in filing for FDA approval of its experimental therapy DYNE-101 for myotonic dystrophy type 1, revising its enrollment timeline for the Phase 1/2 global ACHIEVE trial [3] - Following the announcement of the delay, Dyne's stock price dropped by $2.96, or 21.42%, closing at $10.86 per share [4] Group 2 - The revised schedule for the ACHIEVE trial indicates that Dyne now aims to complete enrollment in the fourth quarter of 2025, with data readout expected in mid-2026 and a potential Accelerated Approval submission in late 2026 [3]